Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Japan to Survey Drug Waste at Pharmacies amid Rising Concerns Over Disposal Costs
July 11, 2025
- Generic and Wholesaler Groups Call for Pricing Reforms to Reflect Inflationary Pressures
July 11, 2025
- 16 Drugs Enter Japan Trials after Pro-Innovation Reform: Industry Poll
July 10, 2025
- Leqembi Likely to Face 15% Price Cut Under Special CEA Rule
July 10, 2025
- Janssen’s Balversa Gets Green Light for NHI Listing
July 10, 2025
- Pharma Groups Renew Push for Price Stability During Patent Term as FY2026 Reform Talks Begin
July 10, 2025
- Trade Groups Urge Pricing Overhaul for Regenerative Medicines, Biotech Drugs
July 10, 2025
- PMDA to Clarify Position on Japanese PI Trials at August Symposium amid Industry Confusion
July 10, 2025
- J-ENTRY Consortium Steps Up to Develop Two “Drug Loss” Products
July 9, 2025
- Vyjuvek Gel, 1st Topical Gene Therapy, Poised for Approval in Japan
July 8, 2025
- Japan Panel Backs Shift to PCV20 for Pneumococcal Vaccination in Elderly
July 8, 2025
- AMED to Promote Earlier Out-Licensing to Industry to Bridge the “Devil’s River”: New Chief
July 8, 2025
- Semaglutide, Tirzepatide, and More Drugs under PMDA Safety Review
July 7, 2025
- Japan to Overhaul Diabetes Trial Guidelines to Align with Global Standards and Prevent Drug Lag/Loss
July 7, 2025
- Healthcare-Linked Candidates Launch Campaigns as Upper House Election Gets Underway
July 4, 2025
- Upper House Campaign Begins in Japan, Healthcare and Pharma-Linked Candidates in Spotlight
July 3, 2025
- Ex-Health Minister Takemi Vows to Bolster Japan’s Drug Development and Supply Resilience
July 2, 2025
- MHLW Shuffles Senior Bureaucrats, Miyamoto to Head Pharma Safety Bureau
July 2, 2025
- LDP’s Honda Pledges Strong Support for Pharma Sector via Pro-Innovation Pricing and Supply Stabilization
July 2, 2025
- Japan Publishes 2025 Strategy Report on Clinical Trials, Backs Single IRB as General Rule
July 1, 2025
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…